Kenvue Inc. (NYSE:KVUE) Shares Sold by Bayesian Capital Management LP

Bayesian Capital Management LP lowered its stake in Kenvue Inc. (NYSE:KVUE) by 66.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,111 shares of the company’s stock after selling 46,000 shares during the quarter. Bayesian Capital Management LP’s holdings in Kenvue were worth $496,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of KVUE. Beaumont Financial Advisors LLC lifted its position in shares of Kenvue by 3.0% during the fourth quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock worth $377,000 after purchasing an additional 509 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in shares of Kenvue by 51.3% in the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after acquiring an additional 526 shares during the period. Manchester Capital Management LLC lifted its holdings in shares of Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares during the period. Tradition Wealth Management LLC lifted its holdings in Kenvue by 2.8% in the fourth quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock valued at $458,000 after acquiring an additional 575 shares during the period. Finally, MV Capital Management Inc. lifted its holdings in Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after acquiring an additional 642 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE traded down $0.20 during trading on Wednesday, reaching $18.55. 526,294 shares of the company were exchanged, compared to its average volume of 18,826,484. The stock has a market cap of $35.52 billion, a P/E ratio of 24.03, a PEG ratio of 2.08 and a beta of 1.40. The firm has a 50 day moving average of $18.55 and a 200 day moving average of $19.48. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.43.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. The firm had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. Kenvue’s revenue was down 24.9% on a year-over-year basis. On average, sell-side analysts forecast that Kenvue Inc. will post 1.13 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 4.42%. The ex-dividend date of this dividend is Wednesday, August 14th. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is 102.56%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Citigroup dropped their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. HSBC lifted their price target on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. Deutsche Bank Aktiengesellschaft lowered their price target on Kenvue from $24.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, July 25th. JPMorgan Chase & Co. lowered their price target on Kenvue from $23.00 to $22.00 and set an “overweight” rating for the company in a report on Monday, July 22nd. Finally, Sanford C. Bernstein started coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $22.45.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.